From-Pfizer

Customer No. 28880

## Confirmation No. 5592

PTO/SB/21 (09-04) Approved for use through 07/31/2005. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE lection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no cersons are required to respond to a co Application Number 10/089.819 RECEIVED Filing Date TRANSMITTAL August 2, 2002 CENTRAL FAX CENTER First Named Inventor **FORM** John Hughes, et al. Art Unit 1617 4UG 3 0 2006 Examiner Name Shahnam Sharareh (to be used for all correspondence after initial filing) Attorney Docket Number PC17885A (A0000005/1) Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition (Appeal Notice, Briof, Roply Brief) Amendment/Repty Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please identify Terminal Disclaimer below): Extension of Time Request Statement as Provided by 37 CFR Request for Refund Express Abandonment Request 1.97(b) CD, Number of CD(s) Supplemental Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Authorization to charge the fee and any additional fees as necessary or credit Reply to Missing Parts/ any overpayment to Deposit Account Warner-Lals hereby given. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Warner-Lambert Company LLC Signature Printed name David R. Kurlandsky 30/00 Reg. No. Date 41.505 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Yradamerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTÓ Fax No.

Typed or printed name

571-273-8300

Ŀĭnda A. Zerby

Customer No. 28880

01 FC:1806

PTO/SB/17 (01-05) Approved for use through 07/31/2008. OMB 0651-0032

Under the Paperwork Reduct	on Act of 1995	I no persons àre rêût	ired to res	U.S. Paten) gond to a collectiv	n of Infor	mation unles:	s it displays a va	MENT OF COMMERCE
						Complete	If Known	
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).				Application Nur	nber	10/089,8	19	
FEE TR	Filing Date Aug		August 2	ist 2, 2002				
Fo	r FY 2	006		First Named Inc	ventor	John Hu	ghes, et al.	CENTRAL FAX CEN
	Examiner Name	В	Shahnar	n Sharareh	AUG_3_0_200			
Applicant claims small	<u></u> [	Art Unit		1617				
TOTAL AMOUNT OF PAY	MENT (\$	180.00		Attorney Docke	t No.	PC1788	5A	
METHOD OF PAYMEN	T (check al	that apply)						
Check Credit	Card 1	Money Order	None	Other (	olease id	entify):		
Deposit Account		•					er-Lambert C	ompany LLC
For the above-ident	fled deposit	account, the Direct	or is here					
Charge fee(s								for the filing fee
·		(s) or underpayme	nts of fee	=		emayments	•	_
under 37 CFI WARNING: Information on thi	1 has 2t t C	17			•			e credit card
nformation and authorization	on PTO-2038	·			_			
FEE CALCULATION (A	II the fees	below are due i	ıpon fili	ng or may be	subje	ct to a sur	charge.)	
1. BASIC FILING, SEAI	RCH, AND	EXAMINATION I	FEES	4555	=>< 4		FEEG	
	FILING	FEES imail Entity	SEARC	H FEES Small Entity	EXAI	MINATIÓN Small	i rees Entity	
Application Type	Fee (\$)	Fee (5)	<u>Fee (\$)</u>	Fee (\$)	Fee			Fees Paid (\$)
Utility	300	150	500	250	20	0 10	0 _	
Design	200	100	100	50	13	0 6.	5 -	
Plant	200	100	300	150	16	0 8	0 –	<del></del>
Reissue	300	150	500	250	60	0 30	0 –	· ·
Provisional	200	100	0	0	(	0	0 _	II = .24
2. EXCESS CLAIM FÉI Fee Description	ES					F		ell Entity see (\$)
Each claim over 20 (	including R	cissues)				•	50	25
Each independent cla			es)				200	100
Multiple dependent o		For (8)	F 1	n_i_ (e)	•		360 <u>Iltiple Depan</u>	180
Total Claims - 20 or HP =	Extra Clair	<u>rs Foo (\$)</u> x 50.00		<u>Paid (\$)</u> ).00			.ee (2) 1000te bebeur	Fee Paid (\$)
HP = highest number of total	claims paid fo					_	60.00	
Indep. Claims - 3 or HP =	Extra Clair			<u>Pald (\$)</u> .00				
HP = highest number of inde	pendent dalm:							
ADDITION SIZE	CCC				-1	.:!! £1.	a anguanna h	or computer
If the specification and listings under 37 C	arawings i FR 1 52(c))	the application	sur pape size fee	due is \$250 (S	\$125 fo	r small en	tity) for each	additional 50
sheets or fraction th	creof. See	35 U.S.C. 41(a)(	(1)(G) at	nd 37 CFR 1.1	6(s).			
Total Sheets	Extra Shee	<u>its Numbo</u>	<u>r of pach</u>	additional 50 c	<u>or fracti</u>	on thereof	<u>Fee (\$)</u> 250.00	Fee Pald_(\$) = 0.00
- 100 = . OTHER FEE(S)		/50 =		•		anno, A	200.00	Foos Paid (5)
Non-English Specific Other (e.g., late filing			-		i			180.00
	,gc	/-momauon_b		- Aretemielli				
IBMITTED BY	11 17	<del>}</del>	l D.	edistration No.			Tolonhone -	04) 000 7004
nature ()		يىلىم	L	egistration No. ¿	11,505		reseptions (7	34) 622-7304
me (Print/Type) David R					•		Date 8/2	Valaca

This collection of information is required by S7 CFR 1.138. The Information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patente, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## Confirmation No. 5592

PC17885 (A0000005/1)

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT

: John Hughes, et al.

EXAMINER : Shahnam J. Sharareh

SERIAL NO.

: 10/089,819

ART UNIT

: 1617

RECEIVED CENTRAL FAX CENTER

FILED

: August 8, 2002

PAPER NO

AUG 3 0 2006

FOR

: Synergistic Combinations of an NK<sub>1</sub> Receptor Antagonist and a GABA

Structural Analog

## Statement as Provided by 37 C.F.R. 1.97(c)

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The Applicants submit that the Supplemental Information Disclosure Statement submitted herewith is being filed after the period specified in paragraph 37 C.F.R. § 1.97(d) and before a notice of allowance under § 1.311, and/or an action that otherwise closes prosecution in the application. Further that each item of information contained in the supplemental information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

As such, the Applicants respectfully requests consideration of the enclosed Supplemental Information Disclosure Statement and request that all references cited herein be printed on the face of the patent upon grant of the application.

It is understood by the Applicants that this paper requires a fee in accordance with 37 C.F.R. § 1.17 (p) and authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

David R. Kurlandsky

Registration No. 41/505

Wamer-Lambert Company LLC

2800 Plymouth Read Ann Arbor, MI 48105

Telephone: (734) 622-7304 Facsimile: (734) 622-1553

7346221269

Confirmation No. 5592

PTO/3B/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449/PTO				e required to reapond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
				Application Number	10/089,819		
			CLOSURE	Filing Date	August 8, 2002	RECEIVED CENTRAL FAX CEN	
STATEMENT BY APPLICANT		First Named Inventor	John Hughes, et al.				
				Art Unit	1617	AUG 3 U 200	
(Use as many sheets as necessary)		Examiner Name	Shahnam Sharareh				
Sneet	1	of	1	Attorney Docket Number	PC17885A (A0000005/	(1)	

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		CUMBERBATCH, M.J. et al., "Reversal of Behavioural and Electrophysiological Correlates of Experimental Paripheral Neuropathy by te NK1 Receptor Antagonist GR205171 in Rats", Neuropharmacology, 1998, pp 1535-1543, Vol 37, No 12	
		DIONNE, R. A. et al., "The Substance P Receptor Antagonist CP-99-994 Reduces Acute Postoperative Pain", Clin Pharmacol Ther, 1998, pp 562-568, Vol 64, No 5	
		FIELD, M.J. et al., "Evatuation of Gabapentin and S-(+)-3-isobuty/gabs in a Rate Model of Postoperative Pain", The Journal of Pharmacology and Experimental Therapeutics, 1997, pp 1242-1246, Vol. 282, No. 3	
		FIELD, M.J. et al., "Gabapentin and Pregabatin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by strptozocin in the rat", Pain, 1999, pp 391-398, Vol. 8	
		•	
, , , , <del>, , ,</del> ,			
	,		=

Examiner	Date	
Signature	Considered	

if you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicants unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is statched.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or rotain a bonofit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the includical case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.